Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Hbm Holdings Ltd (2142)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
10.40 +0.90    +9.47%
08:59:59 - Closed. Currency in HKD
Type:  Equity
Market:  Hong Kong
ISIN:  KYG4403H1002 
  • Volume: 16,080,580
  • Bid/Ask: 10.40 / 10.40
  • Day's Range: 9.31 - 10.42
Hbm 10.40 +0.90 +9.47%

Hbm Holdings Ltd Company Profile

 
Get an in-depth profile of Hbm Holdings Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

183

Equity Type

ORD

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for treating myasthenia gravis; Porustobart HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 for treating melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm. It is also developing HBM7020 for treating hematologic carcinoma and autoimmune diseases; HBM9378 for the treatment of asthma and chronic obstructive pulmonary disease; and HBM1020, HBM1022, HBM9014, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for treating solid tumors. The company was incorporated in 2016 and is based in Suzhou, the People’s Republic of China.

Contact Information

Address Building A3 Suite 202
218 Xinghu Street Suzhou Industrial Park Suzhou, 215123
China
Phone 86 512 6579 0025
Fax -

Top Executives

Name Age Since Title
Jon Marc Wigginton - 2020 Member of Scientific Advisory Board
Xiaoping Ye 62 2020 Independent Non-Executive Director
Yiping Rong 47 2022 Chief Scientific Officer & Executive Director
Peter F. Moesta - - Member of Scientific Advisory Board & Chief CMC Advisor
Robert A. Kramer - 2016 Member of Scientific Advisory Board
Frank Grosveld - 2016 Member of Scientific Advisory Board
Jingsong Wang 60 2016 Founder, Chairman & CEO
Robert Irwin Kamen 81 2016 Independent Non-Executive Director & Member of Scientific Advisory Board
Albert R. Collinson 66 2023 Independent Non-Executive Director
Weiwei Chen 59 2020 Senior Business Adviser & Independent Non-Executive Director
Zhigang Tian - 2020 Member of Scientific Advisory Board
Jon Marc Wigginton 63 2020 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2142 Comments

Write your thoughts about Hbm Holdings Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email